

JUL. 22. 2003 4:54PM

FISH&RICHARDSON\_617-542-8906

NO. 9032 P. 3

Applicant : Zheng Xin Dong  
Serial No. : 09/857,636  
Filed : June 7, 2001  
Page : 2 of 4

Attorney's Docket No.: 00537-186002 / BPC089/WO

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1 to 9 (Cancelled).

10. (Currently amended) A compound according to claim 9 wherein said compound is  
[Aib<sup>8,35</sup>]hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:2),  
[Aib<sup>8</sup>, β-Ala<sup>36</sup>]hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:5),  
[Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup> (N<sup>6</sup>-tetradecanoyl)]hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:7),  
[Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup> (N<sup>6</sup>-tetradecanoyl)]hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:8),  
[Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup> (N<sup>6</sup>-decanoyl)]hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:9), or  
[Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup> (N<sup>6</sup>-tetradecanoyl), β-Ala<sup>37</sup>]hGLP-1(7-37)-OH (SEQ ID NO:14), or a  
pharmaceutically acceptable salt thereof.

11. (Currently Amended) A pharmaceutical composition comprising an effective amount of a compound according to claim 10 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

12. (Currently Amended) A method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 10 or a pharmaceutically acceptable salt thereof.

JUL. 22. 2003 4:54PM

FISH&amp;RICHARDSON\_617-542-8906

Applicant : Zheng Xin Dong  
Serial No. : 09/857,636  
Filed : June 7, 2001  
Page : 3 of 4

Attorney's Docket No.: 00537-186002 / BPC089/WO

13. (Currently Amended) A method of treating a disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease, in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 10 or a pharmaceutically acceptable salt thereof.

14. (Original) A method according to claim 13 wherein said disease is Type I diabetes or Type II diabetes.

Claims 15-18 (Cancelled).